Islet amyloid polypeptide (IAPP) aggregates to form amyloid fibrils in patients with type 2 diabetes and acts as a potent stimulus for interleukin-1β (IL-1β) secretion in bone marrow-derived macrophages. We sought to determine the contribution of resident islet macrophages to IAPP-induced inflammation and beta cell dysfunction. In cultured islets, amyloid. These data provide the first evidence that IAPP aggregates skew resident islet macrophages toward a pro-inflammatory phenotype and suggest a mechanism by which anti-inflammatory therapies may protect beta cells from IAPP-induced islet dysfunction.
INTRODUCTION
Islet amyloid formation (1), macrophage infiltration (2) , and elevated expression of proinflammatory cytokines (3) are associated with beta cell dysfunction in patients with type 2 diabetes. Emerging evidence suggests that early aggregates of islet amyloid polypeptide (IAPP), the principal component of islet amyloid, interact directly with innate immune cells to promote the synthesis of pro-inflammatory cytokines, in particular IL-1β (4, 5) .
Other amyloidogenic peptides also trigger an innate immune response by activating cellsurface pattern recognition receptors (6) in addition to the NACHT, LRR and PYD domain-containing protein 3 (NLRP3) inflammasome (7) . Indeed, aggregates of human IAPP (hIAPP) but not non-amyloidogenic rodent IAPP (rIAPP) induce Il1b mRNA in bone marrow-derived macrophages (BMDMs) (5) and also activate NLRP3 leading to proIL-1β cleavage by caspase-1 (4) . Consistent with an important role for IAPP-induced IL-1 signaling in beta cell dysfunction, IL-1 receptor antagonist (IL-1Ra) improves glucose tolerance in recipients of human IAPP-expressing mouse islet transplants (5) .
Notably, differential expression of IL-1-related genes is a marked characteristic of islets from patients with type 2 diabetes (8) , and recent clinical studies suggest improved insulin secretion in response to anti-IL-1 therapy in these patients (9) .
Both beta cells (10) (11) (12) (13) and macrophages (14, 15) are potential sources of proinflammatory cytokines within the islets of patients with type 2 diabetes. Healthy mouse islets each contain 8-10 macrophages in close association with the vascular endothelium, which are characterized by cell surface expression of CD11b, CD11c, F4/80, and MHC class II (16) . Highly phagocytic and with limited migratory capacity, these resident monocyte-derived cells are functionally more similar to macrophages than dendritic cells (17) and play an important role in immune surveillance (16) . Amyloid-associated macrophages are a major source of cytokines such as IL-1β in other amyloid diseases (18, 19) , and IAPP fibrils have been observed within human islet macrophage lysosomes (20) . The aim of this study was to determine whether IAPP aggregates alter the phenotype of resident islet macrophages and to assess the consequences for islet function. Islet and cell culture. Mouse islets were isolated by ductal collagenase injection and filtration (23) . Islets were maintained at 37°C with 5% CO 2 in RPMI 1640 supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM Glutamax, and 10% FBS. Gene expression analysis. RNA was isolated with a Purelink RNA micro kit (Invitrogen). For analysis of islet gene expression without a preceding culture period, islets were allowed to recover for 4 h following isolation prior to lysis. cDNA was synthesized using a qScript cDNA synthesis kit (Quanta Biosciences, Gaithersburg, MD).
RESEARCH DESIGN AND METHODS

Mice
RT-qPCR was performed with Fast SYBR Green PCR Master Mix (Applied Biosystems, Warrington, UK), and reactions were run on an ABI 7500 Fast Real-Time PCR System.
Primer sequences were obtained from PrimerBank (27) Fig 1A,B) . Expression of MHC class II but not CD11b or F4/80 was significantly decreased after 5 days (Fig 1C) , suggesting a phenotypic change but no alteration in cell number. Consistent with these data, expression of the macrophage genes Emr1 and Itgam and the beta cell genes Pdx1, Ins1, and Ins2 did not change during the culture period (Fig 1D) .
To determine the effect of hIAPP on islet pro-inflammatory gene expression, we treated isolated islets with synthetic IAPP for 4 h. Both hIAPP and the TLR2 ligand FSL-1 induced expression of genes encoding the pro-inflammatory cytokines TNF-α, IL-1β, IL-1α, IL-6, and the chemokine CCL2 in islets compared to non-amyloidogenic rIAPP (Fig 2D, S3) . We did not observe effects of hIAPP on IL-12 family members such as IL-12p40 (Fig S3) , IL-12Rb1, or IL-12Rb2 (not shown), or on the endoplasmic reticulum stress markers CHOP (Ddit3) or BiP (Hspa5; Fig S3) . To determine the contribution of macrophages to hIAPP-induced islet inflammation, freshly-isolated islets were treated with clodronate-containing liposomes, which are selectively toxic to phagocytes (26) . Clodronate reduced the number of F4/80-expressing islet cells as determined by immunostaining (Fig 2A) and reduced expression of macrophage but not beta cell markers (Fig 2B,C) . Phagocyte depletion completely prevented hIAPP-induced expression of pro-inflammatory cytokines. Similarly, phagocyte depletion prevented upregulation of Nlrp3 ( Fig 2D) and Casp1 (Fig S3) . Ccl2 expression was reduced by only 80%, suggesting that non-phagocytic cells, likely beta cells (5), also contribute to islet hIAPP-induced CCL2 production. The anti-inflammatory genes Il10 and Il1rn (encoding IL-10 and IL-1Ra, respectively) were also induced by hIAPP and blocked by clodronate liposome pre-treatment (Fig 2D) , consistent with their upregulation in response to other acute pro-inflammatory stimuli and with transcriptional regulation by NF-κB (31, 32) .
These data indicate that macrophages are major contributors to hIAPP-induced expression of both pro-and anti-inflammatory cytokines in cultured islets.
Synthetic hIAPP induces synthesis of mature IL-1β in macrophages but not other islet cell types. We next assessed the kinetics of IL-1β production in response to aggregating hIAPP. hIAPP but not rIAPP formed amyloid fibrils, as determined by a red shift in the thioflavin-T emission spectrum (Fig 3A) . ProIL-1β was markedly increased in hIAPP-treated BMDMs compared to rIAPP-treated cells within 2 h of exposure to freshly dissolved peptide (Fig 3B,C) , suggesting induction of proIL-1β synthesis by pre-fibrillar aggregates prior to the plateau phase of the hIAPP aggregation curve. IL-1β was detected by ELISA in BMDM supernatants after 24 h ( Fig 3E) and confirmed by western blot to comprise the mature 17 kDa form ( Fig 3F) . Significant levels of mature IL-1β were not detected until 4-24 h after dissolution of the peptide (Fig. 3F) , suggesting that the NLRP3
inflammasome is activated by a fibrillar hIAPP species, following stimulation of proIL-1β synthesis and inflammasome priming by pre-fibrillar hIAPP aggregates. No induction of IL-1β was detected in whole islets, consistent with synthesis by a rare nonbeta-cell population (Fig 3D,E) . Indeed, total IL-1β protein was induced by hIAPP in CD11b + but not CD11b -islet cells, as determined by imaging flow cytometry (Fig 3G,H modest increase in beta cell Pdx1 expression, with no effect on Ins2 mRNA (Fig 6G) .
Consistent with our in vitro macrophage depletion, clodronate liposome administration reduced islet expression of Il1b and Nlrp3 (Fig 6H) , in addition to the anti-inflammatory cytokines Il10 and Il1rn (Fig 6I) . Moreover, islets pre-treated with clodronate liposomes prior to culture under conditions that promote amyloid formation had increased insulin content and improved glucose-stimulated insulin secretion (Fig S6) , providing further evidence that macrophage depletion affects islet function independent of systemic effects.
Taken together, these data suggest that islet macrophages impair islet function in the presence of hIAPP and that they are the major source of both pro-and anti-inflammatory cytokines in islets in vivo.
Because islet macrophages could contribute to either the formation of islet amyloid (by inducing beta cell dysfunction) or its clearance (by removing IAPP aggregates), we next asked whether macrophage depletion affects amyloid severity. We generated obese hIAPP Tg/o mice expressing the agouti viable yellow allele, since these mice develop extensive islet amyloid formation associated with beta cell dysfunction (22) . Islet macrophages were frequently found associated with thioflavin-S-positive amyloid fibrils in hIAPP Tg/o mice ( Fig 7A) . Clodronate liposome treatment significantly reduced fasting hyperglycemia in hIAPP Tg/o but not wild-type mice ( Fig 7B) . As in the
HFD-fed FVB mice, clodronate liposome administration reduced islet Il1b and increased
Pdx1 expression (Fig 7C) . Interestingly, the improved glycemia in clodronate liposometreated mice was associated with increased, rather than decreased, amyloid severity ( Fig   7D ,E) and an increase in the average area of each amyloid deposit ( Fig 7F) with no change in islet area ( Fig 7G) . These data point to a discordance between amyloid deposition and islet function and suggest that pre-fibrillar hIAPP aggregates (present in the absence of thioflavin-S-positive plaques) rather than mature fibrils are the major species associated with islet dysfunction in this model.
DISCUSSION
Anti-inflammatory agents represent a promising approach to treat type 2 diabetes, and several recent clinical trials have suggested that targeting IL-1 signaling can improve insulin secretion (9) . Indeed, recombinant IL-1Ra improves beta cell function in patients with type 2 diabetes without altering insulin sensitivity (37) , suggesting that islets are particularly susceptible to IL-1-mediated damage. We (5) and others (4) have provided evidence that hIAPP acts as a potent stimulus for macrophage activation and islet chemokine release, with a critical role for IL-1β in amplification of this response.
Because phagocytic cells help clear other amyloidogenic peptides (38) , resident islet macrophages might also protect beta cells from IAPP aggregates. The major finding of the current study is that -despite their possible role in limiting extracellular amyloidphagocytic cells are required for IAPP-induced islet inflammation and dysfunction.
Previous studies have demonstrated depletion of up to 98% of islet macrophages after 4-7 days of low temperature culture at 22-24°C in CMRL (15, 30, 39) . Macrophage depletion in RPMI at 37°C has also been reported based on reduced MHC class II staining (40,41). Our data suggest no change in the size of the islet macrophage population based on CD11b and F4/80 expression after 5 days in RPMI at 37°C, despite decreased MHC class II expression. Thus, macrophages must be considered a major source of both pro-and anti-inflammatory cytokines. Indeed, macrophages were required for islet cytokine induction by both hIAPP and the TLR2 ligand FSL-1, although Ccl2 expression levels were similar in FACS-sorted macrophages compared to other cell types, consistent with beta cell production of CCL2 (5, 14) .
These data provide the first direct evidence that resident macrophages are the major source of hIAPP-induced islet IL-1β. Masters et al. were unable to detect IL-1β in supernatants from hIAPP-treated islets (4), consistent with our western blot and ELISA data suggesting that the islet macrophage population is too small to significantly affect total islet IL-1β. One previous report used immunocytochemistry to demonstrate IL-1β expression induced by LPS and TNF-α in islet macrophages but not beta cells (39) , although beta cells may be an important source of IL-1β in response to other stimuli, including double-stranded RNA and elevated glucose (10) (11) (12) (13) 42) . Our data point to a model in which pre-fibrillar IAPP aggregates contribute to priming of the NLRP3 inflammasome and induction of Il1b mRNA in resident macrophages but not beta cells.
NLRP3 activation by larger IAPP species likely occurs later in the course of hIAPP aggregation, when we observed cleavage of proIL-1β. Thus, like other amyloidogenic peptides, hIAPP delivers both signal 1 (for proIL-1β expression) and signal 2 (for proIL-1β processing) required for IL-1β secretion. Interestingly, we also observed limited induction of proIL-1β in BMDMs treated with non-amyloidogenic rIAPP (Fig 3D) .
Monomeric IAPP is a weak agonist for the calcitonin gene-related peptide (CGRP)
receptor (43), and since CGRP can enhance IL-1β synthesis (44), it is possible that rIAPP may also exert its effects via this pathway. This observation is unlikely to be due to microbial contaminants in the synthetic peptide as rIAPP did not activate TLR2 or TLR4.
Furthermore, proIL-1β induction was not observed in rIAPP-treated islet macrophages by imaging flow cytometry and may therefore be cell-type specific.
The most striking differences in gene expression in islets from hIAPP clearance of pre-fibrillar oligomers -or to decreased clearance of mature fibrils, which are phagocytosed by macrophages (55). Importantly, mature IAPP fibrils may be less damaging to the islet than pre-fibrillar oligomers (56), consistent with the discordance between increased fibril deposition and reduced fasting glycemia in our model. As macrophages are a major source of islet IL-1 and our previous work suggested that blockade of the IL-1 receptor limits islet amyloid formation in transplanted islets (5), the extent of amyloid deposition at the beginning of treatment and macrophage activities other than cytokine secretion are likely critical in determining the islet amyloid burden.
Islet macrophages contribute to beta cell dysfunction by secreting IL-1β and other cytokines (15, 30, 39) , although low levels of IL-1β are also important for normal beta cell function (57,58). Our findings suggest that resident islet macrophages, by chronic production of IL-1β in response to IAPP aggregates, may be important contributors to the pathogenesis of type 2 diabetes. Indeed, our data point to islet macrophages as the major source of islet IL-1β in response to IAPP aggregation. Thus, despite their apparent capacity to limit extracellular amyloid fibrils, inhibition of the interaction between macrophages and IAPP and suppression of macrophage IL-1β synthesis are potential therapeutic strategies to improve beta cell function in type 2 diabetes. Figure S3 . Additional gene expression analysis of IAPP-treated islets. Islets were isolated from 12-wk-old C57BL/6 mice and immediately treated with clodronate-containing liposomes (CLODlip, 1 mg/ml clodronate) or control liposomes (PBS-lip) for 36 h, then washed and allowed to recover for 6 h prior to incubation with human IAPP (hIAPP, 10 µM) or the TLR2 ligand FSL-1 (10 ng/ml) for 4 h. mRNA expression of (A) CD11c, (B) inflammasome-related genes, (C) ER stress markers, and (D) cytokines was assessed by RT-qPCR and expression levels were normalized to the housekeeping gene Rplp0. Data represent mean ± SEM of islets from 4 mice and are representative of 3 independent experiments. *p<0.05, **p<0.01, *** p<0.001. 
